A Randomized, Double-blind (Sponsor Unblinded), Placebo Controlled, Repeat Dose Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin
Phase of Trial: Phase II
Latest Information Update: 18 Aug 2017
At a glance
- Drugs GSK 2330672 (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 Sep 2013 New trial record